426 completed, 41 unknown, 30 terminated, 26 recruiting. 558 Phase 3, 42 Phase 2.
Follow Pulmonary Disease, Chronic Obstructive: new trials by email Literature Review of Pulmonary Disease, Chronic Obstructive trials Research Report on Pulmonary Disease, Chronic Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease Verducatib, Placebo matching verducatib - Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 1800 | 2027-03-10 | 2026-10-30 |
| Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg, Comparator - Trimbow® - Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | Eurofarma Laboratorios S.A. | 1252 | 2027-01-30 | 2026-10-26 |
| Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) Ensifentrine, Placebo, Standard of Care (SOC) - Pulmonary Disease, Chronic Obstructive | Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 2136 | 2026-10-23 | 2026-10-15 |
| A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease zelicapavir, Placebo - RSV | Phase 2 / Phase 3 | Recruiting | Enanta Pharmaceuticals, Inc | 860 | 2026-10-19 | 2026-11-02 |
| A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Placebo, REGEND001 - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Not yet recruiting | Regend Therapeutics | 102 | 2026-10-01 | 2026-09-24 |
| A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time Tilrekimig - Moderate to Severe Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | Pfizer | 1360 | 2026-09-21 | 2026-09-24 |
| A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD) Lunsekimig - Chronic Obstructive Pulmonary Disease | Phase 3 | Enrolling by invitation | Sanofi | 1508 | 2026-09-16 | 2026-10-21 |
| A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2) GSK5784283, Placebo, Standard of care - Pulmonary Disease, Chronic Obstructive | Phase 3 | Recruiting | GlaxoSmithKline | 624 | 2026-09-11 | 2026-09-25 |
| A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1) GSK5784283, Placebo, Standard of care - Pulmonary Disease, Chronic Obstructive | Phase 3 | Recruiting | GlaxoSmithKline | 624 | 2026-08-27 | 2026-09-09 |
| A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD HSK39004 Inhalation Suspension, Placebo control - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 387 | 2026-07-11 | 2026-06-22 |
| Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD HSK39004 Inhalation Suspension - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 300 | 2026-07-10 | 2026-06-08 |
| Non-invasive Ventilation or CPAP in OSA-COPD Following Admission for an Acute Hypercapnic Respiratory Failure Non-invasive Ventilation (NIV), Continous Positive Airway Pressure (CPAP) - Chronic Obstructive Pulmonary Disease Exacerbation, Obstructive Sleep Apnea Exacerbation | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 386 | 2026-06-03 | 2026-06-09 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD HSK39004 Dry Powder Inhaler Simulant, HSK39004 Dry Powder Inhaler-0.75mg - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 376 | 2026-05-24 | 2026-06-10 |
| A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) Alpha-1 15%, Liquid Alpha1-PI - Alpha 1 Antitrypsin Deficiency | Phase 3 | Recruiting | Grifols Therapeutics LLC | 40 | 2026-05-05 | 2026-10-26 |
| Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2 - Chronic Obstructive Pulmonary Disease, COPD | Phase 3 | Recruiting | AstraZeneca | 59 | 2026-05-05 | 2026-10-16 |
| Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease TQC3721 Suspension for Inhalation - Chronic Obstructive Pulmonary Disease | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 800 | 2026-04-14 | 2026-09-28 |
| A Phase 3 Trial of JKN2401 Injection in COPD JKN2401 Injection, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Not yet recruiting | Joincare Pharmaceutical Group Industry Co., Ltd | 888 | 2026-03-01 | 2026-01-14 |
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease PF-07275315 dose 1, PF-07275315-dose 2, Placebo - Moderate to Severe Chronic Obstructive Pulmonary Disease | Phase 2 / Phase 3 | Recruiting | Pfizer | 1156 | 2026-02-11 | 2026-10-22 |
| Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza Vaccination Vaxigrip, antibiotic treatments, percutaneus coronary intervention - Acute Coronary Syndromes (ACS), Pneumonia | Phase 3 | Recruiting | University of Brawijaya | 60 | 2026-01-01 | 2026-05-22 |
| eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation Depemokimab, Placebo - Pulmonary Disease, Chronic Obstructive | Phase 3 | Recruiting | GlaxoSmithKline | 1196 | 2025-10-20 | 2026-07-28 |
Showing 20 of 558. Sign in to see all of them.
Emphysema (34) · Bronchitis, Chronic (31) · Lung Diseases (24) · Lung Diseases, Obstructive (18) · Dyspnea (14) · Pulmonary Emphysema (12) · Respiratory Tract Diseases (12) · Asthma (10) · Bronchitis (9) · Hypertension, Pulmonary (7) · Motor Activity (7) · alpha 1-Antitrypsin Deficiency (7) · Heart Failure (6) · Smoking (6)
Chronic Disease (558) · Disease Attributes (558) · Pathological Conditions, Signs and Symptoms (558) · Pathologic Processes (555) · Respiratory Tract Diseases (546) · Lung Diseases, Obstructive (540) · Lung Diseases (534) · Bronchial Diseases (45) · Infections (42) · Respiratory Tract Infections (38) · Respiration Disorders (30) · Bronchitis (28) · Signs and Symptoms (23) · Signs and Symptoms, Respiratory (18) · Cardiovascular Diseases (17)
Tiotropium Bromide (85) · Formoterol Fumarate (47) · Salmeterol Xinafoate (36) · Glycopyrrolate (35) · indacaterol (35) · olodaterol (26) · Albuterol (24) · indacaterol-glycopyrronium combination (20) · vilanterol (20) · Fluticasone (19) · aclidinium bromide (19) · Roflumilast (18) · GSK573719 (17) · Budesonide (14) · fluticasone furoate (14)
Boehringer Ingelheim (81) · GlaxoSmithKline (65) · AstraZeneca (59) · Novartis Pharmaceuticals (46) · Pearl Therapeutics, Inc. (18) · Chiesi Farmaceutici S.p.A. (16) · Novartis (14) · Henan University of Traditional Chinese Medicine (8) · Sanofi (8) · Sumitomo Pharma America, Inc. (8) · Dey (6) · National Heart, Lung, and Blood Institute (NHLBI) (6) · Pfizer (6) · Aeris Therapeutics (5) · Grifols Therapeutics LLC (5)
United States (240) · Germany (148) · Canada (125) · United Kingdom (102) · Spain (99) · France (85) · Hungary (84) · Poland (84) · Italy (79) · Argentina (74) · South Korea (74) · Russia (72) · Netherlands (69) · China (67) · Belgium (65)
Esther Garcia, MD (11) · Colin Reisner, MD (9) · Esther Garcia, Ph.D. (4) · Chad Orevillo (2) · Colin Reisner (2)
PMID 32943047, PMID 35815359, PMID 42551404, PMID 20102307, PMID 24314123, PMID 28419462, PMID 30077810, PMID 32462607, PMID 32671684, PMID 32848381, PMID 42476723, PMID 21227674, PMID 21397482, PMID 22206353, PMID 24998880, PMID 25496316, PMID 25670896, PMID 27796912, PMID 28074135, PMID 29331313, PMID 30261995, PMID 30584583, PMID 31321713, PMID 32021148, PMID 32450869, PMID 32776202, PMID 19716960, PMID 19716961, PMID 21272339, PMID 21518460, PMID 21814460, PMID 22003288, PMID 22158330, PMID 22177371, PMID 22334770, PMID 22383665, PMID 22544891, PMID 23020650, PMID 23117188, PMID 24120253, PMID 24156566, PMID 24835833, PMID 24966672, PMID 25044280, PMID 25045258, PMID 25187881, PMID 25342898, PMID 25490706, PMID 25573406, PMID 26006754
2009 (15), 2008 (8), 2023 (7), 2014 (3), 2025 (3), U10HL074424 (3), 2005 (2), 2015 (2), 2018 (2), 2019 (2), 2017 (1), K23HL146946 (1), K23HL151758 (1), N01HR761971 (1), P30CA138292 (1)